登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07761286,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Child-Pugh score <7 and no history of hepatic encephalopathy.
入选标准第 5 条
NYHA Class II or higher congestive heart failure, unstable angina, or myocardial infarction occurring within 6 months prior to the first study drug administration;
排除标准第 18 条
No prior systemic anti-tumor therapy for HCC. Prior systemic therapy administered in the neoadjuvant or adjuvant setting is permitted, provided that the time from the last dose of prior therapy to tumor recurrence is ≥6 months.
入选标准第 6 条
Fertile eligible participants (male and female) must agree to use reliable contraceptive methods together with their partners throughout the study period and for at least 7 months after the last study drug administration (hormonal contraceptives, barrier methods, or abstinence). Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment.
入选标准第 16 条
Received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) or any investigational trial intervention within 4 weeks prior to the first study drug administration or within 5 half-lives of the most recent anti-tumor agent (whichever is shorter); or received Chinese patent medicines with anti-tumor indications, palliative radiotherapy, or locoregional therapy within 14 days prior to the first study drug administration.
排除标准第 2 条
Received systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first study drug administration, except for the following scenarios: physiologic replacement doses of hydrocortisone or equivalent hormones (i.e., prednisone ≤10 mg/day or equivalent); topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids; short-course corticosteroids for prophylaxis (e.g., prophylaxis against contrast medium allergy).
排除标准第 4 条
Received strong CYP3A4 inhibitors/inducers, or OATP1B1/OATP1B3 inhibitors within 14 days prior to the first study drug administration, or require continuous use of such agents throughout the study period.
排除标准第 6 条
Active infection requiring intravenous anti-infective therapy within 14 days prior to the first study drug administration.
排除标准第 9 条
History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or intestinal obstruction within 6 months prior to the first study drug administration.
排除标准第 13 条
Prior immunotherapy complicated with Grade ≥3 immune-related adverse events (irAEs) or Grade ≥2 immune-related myocarditis (excluding stabilized immune-related endocrine abnormalities).
排除标准第 28 条
Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
入选标准第 8 条
Hematology: PLT ≥100×10⁹/L; Hb ≥90 g/L; ANC ≥1.5×10⁹/L (no blood transfusion, platelet transfusion or hematopoietic stimulating factor administered within 14 days prior to hematology testing at screening);
入选标准第 11 条
Liver function: AST and ALT ≤5×ULN; TBIL ≤1.5×ULN;
入选标准第 12 条
Coagulation function: APTT ≤1.5×ULN; INR ≤1.5×ULN. Participants receiving full-dose oral anticoagulants must maintain a stable dose for a minimum of 14 days;
入选标准第 14 条
Active hepatitis B at screening [positive HBsAg or HBcAb with active viral replication (HBV DNA ≥2000 IU/mL)]; hepatitis C (positive Anti-HCV antibody with positive HCV RNA PCR); active syphilis infection (positive TP-Ab plus positive TRUST/RPR); HIV infection; or concurrent co-infection with both hepatitis B and hepatitis C.
排除标准第 16 条
Female participants who are pregnant or breastfeeding.
排除标准第 30 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07761286,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The participant voluntarily signs the informed consent form. Aged ≥18 years at the time of informed consent acquisition. Confirmed diagnosis of hepatocellular carcinoma (HCC) via histopathology, cytopathology, or clinical diagnosis in accordance with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2026 Edition). Barcelona Clinic Liver Cancer (BCLC) Stage C; or BCLC Stage B unsuitable for curative surgery and/or locoregional therapy. Child-Pugh score <7 and no history of hepatic encephalopathy. No prior systemic anti-tumor therapy for HCC. Prior systemic therapy administered in the neoadjuvant or adjuvant setting is permitted, provided that the time from the last dose of prior therapy to tumor recurrence is ≥6 months. At least one measurable lesion per RECIST Version 1.1. Lesions previously treated with interventional therapy, radiotherapy or ablation may be counted as measurable lesions if clear disease progression is documented per RECIST v1.1 and the lesion meets measurable lesion criteria. Eastern Cooperative Oncology Group (ECOG) performance status ≤1. Expected survival ≥3 months. Adequate organ function as defined below: Hematology: PLT ≥100×10⁹/L; Hb ≥90 g/L; ANC ≥1.5×10⁹/L (no blood transfusion, platelet transfusion or hematopoietic stimulating factor administered within 14 days prior to hematology testing at screening); Liver function: AST and ALT ≤5×ULN; TBIL ≤1.5×ULN; Renal function: Ccr >50 mL/min (calculated by the Cockcroft-Gault formula); urine protein <2+; participants with urine protein ≥2+ must have a 24-hour urine protein quantification <1 g; Coagulation function: APTT ≤1.5×ULN; INR ≤1.5×ULN. Participants receiving full-dose oral anticoagulants must maintain a stable dose for a minimum of 14 days; Albumin: ≥30 g/L (equivalent to ≥3.0 g/dL). Fertile eligible participants (male and female) must agree to use reliable contraceptive methods together with their partners throughout the study period and for at least 7 months after the last study drug administration (hormonal contraceptives, barrier methods, or abstinence). Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. Willing and able to comply with all study requirements.排除标准:Exclusion Criteria:
Histologically or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma. Received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) or any investigational trial intervention within 4 weeks prior to the first study drug administration or within 5 half-lives of the most recent anti-tumor agent (whichever is shorter); or received Chinese patent medicines with anti-tumor indications, palliative radiotherapy, or locoregional therapy within 14 days prior to the first study drug administration. Underwent major visceral surgery (excluding core needle biopsy) or sustained severe trauma within 4 weeks prior to the first study drug administration, or planned elective surgery during the study period. Received systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first study drug administration, except for the following scenarios: physiologic replacement doses of hydrocortisone or equivalent hormones (i.e., prednisone ≤10 mg/day or equivalent); topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids; short-course corticosteroids for prophylaxis (e.g., prophylaxis against contrast medium allergy). Received live vaccines within 4 weeks prior to the first study drug administration. Note: Seasonal influenza vaccines are inactivated vaccines in general and are permitted. Intranasal influenza vaccines are live vaccines and are prohibited. Received strong CYP3A4 inhibitors/inducers, or OATP1B1/OATP1B3 inhibitors within 14 days prior to the first study drug administration, or require continuous use of such agents throughout the study period. Adverse reactions from prior anti-tumor therapy have not recovered to Grade ≤1 per NCI CTCAE v6.0 (excluding toxicities judged by the Investigator to carry no safety risks, such as alopecia, Grade 2 peripheral neuropathy, hypothyroidism stabilized with hormone replacement therapy, etc.). History of or current central nervous system metastases and/or carcinomatous meningitis; current untreated spinal cord compression (excluding participants with previously diagnosed treated spinal cord compression with documented clinically stable symptoms for more than 2 weeks prior to screening). Active infection requiring intravenous anti-infective therapy within 14 days prior to the first study drug administration. Symptomatic moderate or severe ascites within 14 days prior to the first dose or at screening (excluding minor ascites only visible on imaging without clinical symptoms); or uncontrolled moderate or larger pleural effusion or pericardial effusion. Tumor thrombus involving both the main portal vein and left/right portal branches simultaneously; tumor thrombus involving both the main portal vein and superior mesenteric vein simultaneously; or tumor thrombus involving the inferior vena cava. Esophageal or gastric variceal bleeding secondary to portal hypertension, or any life-threatening bleeding event within 6 months prior to the first study drug administration (including events requiring blood transfusion, surgery, locoregional intervention, or sustained medical treatment); known severe esophageal/gastric varices on endoscopy without definitive treatment within 3 months prior to the first study drug administration; other gastrointestinal bleeding events, active gastric or duodenal ulcer within 28 days prior to screening. History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or intestinal obstruction within 6 months prior to the first study drug administration. Presence of severe unhealed wounds or untreated fractures at screening. Current interstitial pneumonia/interstitial lung disease; prior history of interstitial pneumonia/interstitial lung disease requiring corticosteroid treatment; or other pulmonary conditions that may interfere with the identification and management of immune-related pulmonary toxicity, such as pulmonary fibrosis, organizing pneumonia, active pulmonary tuberculosis, etc. Active hepatitis B at screening [positive HBsAg or HBcAb with active viral replication (HBV DNA ≥2000 IU/mL)]; hepatitis C (positive Anti-HCV antibody with positive HCV RNA PCR); active syphilis infection (positive TP-Ab plus positive TRUST/RPR); HIV infection; or concurrent co-infection with both hepatitis B and hepatitis C. History of severe cardiovascular and cerebrovascular diseases, including but not limited to: NYHA Class II or higher congestive heart failure, unstable angina, or myocardial infarction occurring within 6 months prior to the first study drug administration; Severe cardiac rhythm or conduction abnormalities requiring clinical intervention, such as ventricular arrhythmias, second- or third-degree atrioventricular block (participants may be eligible if the Investigator assesses no significant risks); Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy); Clinically significant history of QT interval prolongation, or QTcF (calculated via Fridericia's formula) > 480 ms at screening, or left ventricular ejection fraction < 50%; Arterial or venous thromboembolic events within 6 months prior to the first study drug administration, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc. Participants with stable thrombosis may be enrolled if the Investigator determines no cardiovascular risks. Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg). Active or recurrent autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for the following conditions: Autoimmune thyroid disease with clinically stable status; Type 1 diabetes managed with hormone replacement therapy; Autoimmune skin disorders well controlled with topical therapy (e.g., low-potency topical corticosteroids) without acute exacerbations requiring additional treatment within 12 months before screening (e.g., eczema, psoriasis, lichen simplex chronicus, or vitiligo involving <10% of total body surface area). Prior immunotherapy complicated with Grade ≥3 immune-related adverse events (irAEs) or Grade ≥2 immune-related myocarditis (excluding stabilized immune-related endocrine abnormalities). Known hypersensitivity to any component of the study treatment; history of hypersensitivity to premedications; or poorly controlled asthma (presentation of three or more asthma symptoms with partially controlled or uncontrolled status). Female participants who are pregnant or breastfeeding. History of other malignant tumors within 2 years prior to the first dose, or concurrent active malignant tumors (participants with cured localized tumors may be enrolled, including basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the prostate, cervical carcinoma in situ, breast carcinoma in situ, etc.). Known alcohol or drug dependence; or other severe systemic medical conditions deemed by the Investigator to render the participant unsuitable for participation in this clinical study for any other reason.
引自 ClinicalTrials.gov, NCT07761286, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07761286,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。